Innovations • Global Impact • In The News • Our People
A Reflection of 2022 - Structure, Focus, and Growth
The successful transition from IDRI to AAHI renewed our focus on pragmatic and creative solutions to fundamental global health challenges and continued development of immune-enhancing technologies that can reach all areas of the world.
The latest scientific breakthroughs at AAHI.
Longer Lasting, Broadly Protective SARS-CoV-2 RNA Vaccine Candidate Stable at Room Temperature
AAHI scientists demonstrate the ability of AAHI's novel SARS-CoV-2 self-amplifying RNA (saRNA) vaccine candidate (AAHI-SC2) to elicit strong antibody and T cell immunity to multiple variants of SARS-CoV-2 and can easily be freeze-dried for long-term room-temperature or refrigerated stability (10+ months).
Adjuvant Formulations Are A Key Component to Developing an Effective Malaria Vaccine
Researchers at Ehime University demonstrate that the use of AAHI's adjuvant formulation induced stronger immunity against malaria in a preclinical study published amidst new findings that mosquito behaviors are changing and insecticide-resistant mosquitos are invading African countries, making it much more difficult to eradicate mosquitos and prevent malaria.
AAHI Adjuvant Formulations Enable Vaccine Dose-Sparing Effect Against Pandemic Influenza
A Phase 1 clinical trial conducted by Instituto Butantan (NCT0330899), demonstrated the use of an adjuvant formulated with an influenza A/H7N9 antigen greatly increased antibody titers. The results show that less antigen can be administered per dose for sufficient protection against disease, allowing more doses to be produced during times of high vaccine demand.
Make your products accessible to those who need them most. Collaborate with AAHI.
Collaboration across communities. Explore AAHI's different areas of impact.
AAHI to share progress on priority Sustainable Development Goals at GlobalWA's Goalmakers Annual Conference
Join us to discuss how we can build solutions to ensure every person has access to life-saving technology, regardless of geography or socio-economic circumstance.
Successful lyophilization of a thermostable subunit tuberculosis vaccine candidate containing an emulsion-based adjuvant
AAHI's tuberculosis vaccine candidate, combining our "ID93" fusion protein and GLA-SE adjuvant formulation, was successfully lyophilized by Lyophilization Technology Inc., published in Frontiers in Drug Delivery. The vaccine candidate is designed for long-term stability.
Cape Town, South Africa
First-in-human Phase 1 / 2 clinical trial evaluating saRNA-NLC SARS-CoV-2 vaccine candidate
AAHI's SARS-CoV-2 RNA vaccine candidate, AAHI-SC2, developed in collaboration with AccessBio (a joint venture between ImmunityBio and Amyris), is currently being evaluated in a Phase 1 / 2 clinical trial sponsored by ImmunityBio in South Africa (NCT05370040). The ongoing trial has demonstrated safety of the vaccine candidate.
Help us make impossible vaccines possible.
IN THE NEWS
By Bob Holmes
"We've spent a lot of time working on adjuvant formulations that can shape the immune response to make it more potent, but also broader and more durable," AAHI's Senior Vice President, Formulations, Christopher Fox, PhD tells Knowable Magazine. Adjuvants are ingredients vaccine developers add to vaccines to tweak the immune system's response and may be the solution to better vaccines.
Collaboration across communities. Explore our different areas of impact.
AAHI was honored to receive the nonprofit "Turnaround of the Year" award from the Turnaround Management Association, which recognized AAHI's reorganization and exit from receivership.
November 1-4 | Boston, Massachusetts
Congratulations to Shelly Crocker LLC, Jennifer Faubion at Cairncross & Hempelmann, Avi Lipman at McNaul Ebel Nawrot & Helgren PLLC, Brett Amron at Bast Amron LLP, Neil O'Connor at Neil O'Connor LLC, Candice Decaire, Chief Strategy Officer and General Counsel, and Dr. Corey Casper, President and Chief Executive Officer.
Openings and Opportunities
The Associate / Staff Scientist will be responsible for managing and executing formulation development
and stability studies, including collecting, analyzing, reviewing, and reporting bulk antigen and drug
product characterization for multiple projects.
The Senior Scientist joining our RNA vaccine team will be responsible for broadening the applications of
AAHI's RNA vaccine platform to a wide range of infectious disease and oncology targets.
Learn more about our formulation technology
We partner with biotech leaders to develop vaccines and more.
Synthetic TLR4 ligand in squalene nanoemulsion
Synthetic TLR4 ligand in QS- 21 containing liposome
Synthetic TLR4 ligand in aqueous formulation
Dual agonist containing both TLR4 and TLR7/8 ligands
Synthetic TLR7/8 ligand in
Synthetic TLR7/8 ligand
adsorbed to aluminum
Synthetic TLR7/8 ligand in
Nanostructured lipid carrier
See how our formulations are being used.
Sign up to stay in touch!
Get the latest news and updates in your inbox every month and learn more about how our scientists are developing equitably accessible vaccines and therapeutics for people who most need them.